Shares of Celgene Co. (NASDAQ:CELG) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $95.44 and last traded at $94.75, with a volume of 437998 shares traded. The stock had previously closed at $95.10.
Several analysts have recently issued reports on CELG shares. Jefferies Financial Group cut shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target on the stock. in a research report on Friday, February 1st. Morgan Stanley cut their target price on shares of Celgene from $93.00 to $88.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 19th. BTIG Research assumed coverage on shares of Celgene in a research note on Thursday, December 20th. They set a “neutral” rating on the stock. ValuEngine upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. Finally, BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, eighteen have given a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $99.41.
The company has a market cap of $66.54 billion, a P/E ratio of 12.39, a P/E/G ratio of 0.43 and a beta of 1.71. The company has a debt-to-equity ratio of 3.21, a quick ratio of 2.12 and a current ratio of 2.23.
In related news, Director Ernest Mario purchased 2,000 shares of the company’s stock in a transaction on Tuesday, February 12th. The shares were bought at an average cost of $89.99 per share, for a total transaction of $179,980.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James J. Loughlin sold 23,466 shares of the stock in a transaction that occurred on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the completion of the transaction, the director now owns 62,102 shares in the company, valued at $5,420,883.58. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.
A number of institutional investors have recently made changes to their positions in CELG. Appleton Partners Inc. MA boosted its holdings in shares of Celgene by 29.8% in the first quarter. Appleton Partners Inc. MA now owns 9,464 shares of the biopharmaceutical company’s stock valued at $893,000 after acquiring an additional 2,173 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of Celgene in the first quarter valued at approximately $12,325,000. Hills Bank & Trust Co. boosted its holdings in shares of Celgene by 11.9% in the first quarter. Hills Bank & Trust Co. now owns 15,883 shares of the biopharmaceutical company’s stock valued at $1,498,000 after acquiring an additional 1,688 shares during the period. Financial Advantage Inc. acquired a new stake in shares of Celgene in the first quarter valued at approximately $4,143,000. Finally, Prime Capital Investment Advisors LLC boosted its holdings in shares of Celgene by 383.9% in the first quarter. Prime Capital Investment Advisors LLC now owns 600 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 476 shares during the period. Institutional investors own 74.81% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Celgene (CELG) Reaches New 12-Month High at $95.44” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.themarketsdaily.com/2019/04/18/celgene-celg-reaches-new-12-month-high-at-95-44.html.
About Celgene (NASDAQ:CELG)
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: FAANG Stocks
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.